A detailed history of Pnc Financial Services Group, Inc. transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, Pnc Financial Services Group, Inc. holds 18,233 shares of BCRX stock, worth $132,553. This represents 0.0% of its overall portfolio holdings.

Number of Shares
18,233
Previous 17,884 1.95%
Holding current value
$132,553
Previous $110,000 25.45%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024

BUY
$6.41 - $8.69 $2,237 - $3,032
349 Added 1.95%
18,233 $138,000
Q2 2024

Aug 09, 2024

BUY
$4.13 - $6.79 $1,751 - $2,878
424 Added 2.43%
17,884 $110,000
Q1 2024

May 10, 2024

BUY
$4.89 - $7.65 $31,946 - $49,977
6,533 Added 59.79%
17,460 $88,000
Q4 2023

Feb 09, 2024

SELL
$4.98 - $6.77 $4,930 - $6,702
-990 Reduced 8.31%
10,927 $65,000
Q3 2023

Nov 13, 2023

SELL
$6.71 - $7.92 $40,380 - $47,662
-6,018 Reduced 33.55%
11,917 $84,000
Q2 2023

Aug 11, 2023

BUY
$6.96 - $8.81 $18,708 - $23,681
2,688 Added 17.63%
17,935 $126,000
Q1 2023

May 15, 2023

BUY
$7.94 - $11.84 $24,034 - $35,839
3,027 Added 24.77%
15,247 $127,000
Q4 2022

Feb 10, 2023

BUY
$10.5 - $14.2 $26,460 - $35,784
2,520 Added 25.98%
12,220 $140,000
Q3 2022

Nov 10, 2022

BUY
$10.79 - $14.81 $53,054 - $72,820
4,917 Added 102.8%
9,700 $122,000
Q2 2022

Aug 12, 2022

BUY
$7.89 - $17.88 $8,765 - $19,864
1,111 Added 30.26%
4,783 $50,000
Q1 2022

May 12, 2022

SELL
$11.56 - $19.76 $17,409 - $29,758
-1,506 Reduced 29.08%
3,672 $59,000
Q4 2021

Feb 11, 2022

BUY
$11.18 - $15.46 $56,895 - $78,675
5,089 Added 5717.98%
5,178 $71,000
Q1 2021

May 07, 2021

BUY
$7.37 - $13.61 $655 - $1,211
89 New
89 $0
Q1 2018

May 11, 2018

SELL
$4.35 - $5.82 $448 - $599
-103 Closed
0 $0
Q4 2017

Feb 09, 2018

BUY
$4.16 - $5.33 $428 - $548
103
103 $0

Others Institutions Holding BCRX

About BIOCRYST PHARMACEUTICALS INC


  • Ticker BCRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,944,992
  • Market Cap $1.35B
  • Description
  • BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...
More about BCRX
Track This Portfolio

Track Pnc Financial Services Group, Inc. Portfolio

Follow Pnc Financial Services Group, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pnc Financial Services Group, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Pnc Financial Services Group, Inc. with notifications on news.